Researchers have spent twenty years fixated on the Laron Paradox—the idea that stalling growth hormone (GH) signaling is our best defense against cancer and aging. It’s a tidy narrative: shut down the engine, and the car won't wear out. It looks like a miracle in mice, but in humans, it’s usually a slow-motion metabolic disaster.

On the flip side, we have the Somatopause Collapse. This hypothesis argues that the age-related drop in GH and IGF-1 isn't an "adaptive buffer" against entropy, but a total systemic surrender. We lose muscle, gain visceral fat, and our neural plasticity just evaporates. We aren't preserving the organism; we’re letting it rust in the garage.

The question is which side wins. If you follow the calorie-restriction-at-all-costs crowd, they’ll tell you to keep IGF-1 low forever. But look at the clinical reality. The FDA’s recent move to drop those misleading warnings on hormone replacement therapy signals a massive shift in perspective. We’re finally realizing that hormonal withdrawal is a pathology, not a program.

I’m betting that Somatopause Collapse is the real driver of human frailty. The Laron Shield works for a species that dies young from predation; it isn't a blueprint for a functional centenarian.

The problem isn’t the growth hormone—it’s the metabolic friction it causes. In my IRS-1 Rescue Hypothesis, I argue that the goal shouldn’t be to suppress growth, but to decouple anabolism from insulin resistance. If we pair GH restoration with SGLT2 inhibitors or AMPK modulation, we can theoretically dodge the glucose spikes while maintaining the muscle and bone density people need to stay out of nursing homes.

Right now, we're funding the avoidance of life rather than its optimization. We need aggressive trials on pulsatile GH restoration paired with metabolic stabilizers. We’re so terrified of a potential "oncogenic tax" that we’re letting a "frailty tax" bankrupt our biology before we even get to the finish line.

It's time to stop starving the machine and start tuning the engine. I’m looking for collaborators to model the IRS-1/SGLT2 synergy in a clinical cohort.